New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2013
20:23 EDTRHHBY, ALXNAlexion's price may be more than Roche would be willing to pay, Reuters says
A Roche (RHHBY) bid for Alexion (ALXN) would mark an attempt by Roche to diversify beyond its core cancer competencies through acquisitions but Alexion's valuation may be more than Roche would be willing to pay, says Reuters. Reference Link
News For ALXN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
06:36 EDTRHHBYImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
July 30, 2015
09:25 EDTRHHBYLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools & Diagnostics Analyst Leonard, along with Dr. Anami Patel and Dr. Nathan Ledeboer, discuss their perspectives on Point-of-Care molecular tests including the opportunity in virology / microbiology, the threat to traditional lab-based testing and point-of-care instruments on an Analyst/Industry conference call to be held on July 30 at 11 am.
06:34 EDTALXNAlexion cuts FY!5 non-GAAP EPS to $4.70-$4.80 from $5.60-$5.80, consensus $4.98
Subscribe for More Information
06:32 EDTALXNAlexion reports Q2 Soliris sales $635.98M
Subscribe for More Information
06:32 EDTALXNAlexion reports Q2 non-GAAP EPS $1.44, consensus $1.38
Subscribe for More Information
05:57 EDTRHHBYRoche submits filing to FDA for companion diagnostic for NSCLC drug therapy
Roche announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval, or PMA, to the FDA, as a companion diagnostic test for AZD9291, an AstraZeneca (AZN) investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. Patients with non-small cell lung cancer who have adenocarcinoma with tumor containing an EGFR sensitizing mutation show significant benefit from currently available EGFR TKI therapies. However, approximately two-thirds of these patients will relapse and develop drug resistance. In many cases, this resistance is caused by an acquired mutation called T790M. The cobas EGFR v2 test can aid clinicians to appropriately select NSCLC patients who have acquired the T790M mutation and are most likely to benefit from AstraZeneca's novel therapy.
July 29, 2015
15:08 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information
July 28, 2015
07:20 EDTALXNBrookings Institute to hold a public meeting
Subscribe for More Information
07:08 EDTRHHBYRoche introduced several diagnostic testing platforms at the AACC 2015
Subscribe for More Information
July 27, 2015
08:38 EDTALXNAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
06:28 EDTALXNAlexion resumed with an Overweight at JPMorgan
Target $249.
July 23, 2015
06:27 EDTRHHBYRoche CEO expects biosimilars in Europe by late 2017, Reuters reports
Subscribe for More Information
05:46 EDTRHHBYRoche expects FY15 sales to grow low- mid-single digits
Expects FY15 core EPS to grow ahead of sales at constant exchange rates. Roche expects to further increase dividend in Swiss francs.
05:45 EDTRHHBYRoche reports 1H15 core EPS CHF 7.22 vs. 7.57 last year
Subscribe for More Information
July 22, 2015
09:28 EDTALXNBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
July 21, 2015
07:05 EDTRHHBY, ALXNOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use